Skip to content

Anticholinergics for Cervical Edema in Labor

Anticholinergics for Cervical Edema in Labor (ACCEL)

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06702670
Acronym
ACCEL
Enrollment
200
Registered
2024-11-25
Start date
2025-03-25
Completion date
2027-04-09
Last updated
2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Labor Dystocia

Keywords

dilation, labor

Brief summary

The purpose of this study is to is to determine the clinical effectiveness of a single dose of intravenous (IV) medication for the prevention of labor arrest and cesarean delivery in primiparous women undergoing trial of labor.

Interventions

DRUGTreatment with Diphenhydramine

Diphenhydramine 50mg IV will be administered within 1 hour of the cervical exam which diagnosed prolonged active phase of labor

COMBINATION_PRODUCTUsual Care

Participants will receive cervical exams every 2 hours in active labor, placement of intrauterine pressure catheter, up titration of Pitocin if contractions are inadequate, maternal repositioning, and use of adjunct devices such as a peanut ball.

Sponsors

The University of Texas Health Science Center, Houston
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Primiparous * Viable single intrauterine pregnancy -≥ 34 weeks of gestation * Ruptured membranes * Category I tracing at time of inclusion * Active phase of labor (\>=6 cm of cervix dilation)

Exclusion criteria

* Category II or III tracing * Allergy to the study medication (IV Diphenhydramine)

Design outcomes

Primary

MeasureTime frame
Number of participants that achieve complete dilation of cervix (10cm)from start of treatment upto 4 hours

Secondary

MeasureTime frameDescription
Number of participants who have vaginal delivery after protracted laborEnd of delivery (an average of upto 6 hours after start of treatment)
Number of participants who have Postpartum complications captured as composite maternal morbidityfrom hospitalization up to 6 weeks postpartumThis includes postpartum hemorrhage, cervical lacerations or intraamniotic infection
Number of neonates that had adverse eventsfrom birth up to 6 weeks post-deliveryAdverse events include 5 minute APGAR SCORES less than 7, Respiratory Support with intubation in the delivery room , Neonatal intensive acre unit (NICU) admission, Fetal Anomalies, Infection, Intraventricular Hemorrhage, Hypoglycemia, Retinopathy of prematurity, Injuries, Fractures

Countries

United States

Contacts

CONTACTSamantha Antonioli, MD
Samantha.Hentosh@uth.tmc.edu(713) 566-5735
CONTACTAaron Roberts
Aaron.W.Roberts@uth.tmc.edu(713) 500-6412
PRINCIPAL_INVESTIGATORSamantha Antonioli, MD

The University of Texas Health Science Center, Houston

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 7, 2026